Catherine Moukheibir - Jun 6, 2024 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role: Director
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Catherine Moukheibir
Stock symbol: MLTX
Transactions as of: Jun 6, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/7/2024, 05:01 PM
Previous filing: Dec 19, 2023
Next filing: Jun 21, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLTX	Option to Buy	Award	$0	+7.69K		$0.00	7.69K	Jun 6, 2024	Class A ordinary shares, par value $0.0001 per share	7.69K	$42.44	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.

Content

This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer.